ACRS
Aclaris Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C
Company Profile
CEO
Neal S. Walker
IPO Date
2015-10-06
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Aclaris Therapeutics, Inc.
CEO
Neal S. Walker
IPO Date
2015-10-06
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 9,330 |
| $4.41 |
| 5 May 2026 | Hall Jesse Wayne | Chief Medical Officer | M-Exempt | Disposed | 36,375 | $0.00 |
| 27 Apr 2026 | Leonard Braden Michael | 10 percent owner | S-Sale | Disposed | 300,000 | $4.53 |
| 3 Mar 2026 | Balthaser Kevin | Chief Financial Officer | M-Exempt | Acquired | 2,375 | $0.00 |
| 3 Mar 2026 | Balthaser Kevin | Chief Financial Officer | M-Exempt | Disposed | 2,375 | $0.00 |
| 3 Mar 2026 | Balthaser Kevin | Chief Financial Officer | F-InKind | Disposed | 677 | $2.87 |
| 6 Feb 2026 | Walker Neal | director, officer: CEO | A-Award | Acquired | 961,700 | $3.61 |
| 6 Feb 2026 | Walker Neal | director, officer: CEO | A-Award | Acquired | 274,800 | $0.00 |
| 6 Feb 2026 | Davis Hugh M. | director, officer: President and COO | A-Award | Acquired | 96,100 | $0.00 |